From: Relevance of internal time and circadian robustness for cancer patients
Age | 63 y.o. (range: 37 – 78) | ||
---|---|---|---|
Sex | Male | 11 | |
Female | 13 | ||
Primary Tumor | Colon or rectal | 21 | |
Pancreas | 2 | ||
Esophagus/cardia | 1 | ||
Number of metastatic sites | 0 | 3 | |
1 | 9 | ||
2 | 3 | ||
≥3 | 9 | ||
WHO-PS | 0 | 18 | |
1 | 6 | ||
2 | 0 | ||
Number of prior CT lines | 0 | 7 | |
1 | 2 | ||
2 | 6 | ||
≥3 | 9 | ||
CT regimen | Chrono FLO | 1 | 3 |
+ CETUXIMAB | 1 | ||
+ DOCETAXEL | 1 | ||
Chrono IF | 1 | 1 | |
Chrono IFL | / | 4 | |
+ BEVACIZUMAB | 2 | ||
+ BEVACIZUMAB + PANITUMUMAB | 2 | ||
Chrono IFLO | 9 | 16 | |
+ CETUXIMAB | 6 | ||
+ BEVACIZUMAB | 1 |